CRRT is a slow and gentle method of dialysis that removes excess fluids and waste products from the blood in a continuous basis, much like the kidneys function in healthy individuals.
Adoption of CRRT for the Treatment of Critically ill Patients with Acute Kidney Injury (AKI) Drives Demand in Continuous Renal Replacement Therapy (CRRT) Market

Acute Kidney Injury (AKI) is a global problem and is common amongst critically ill patients. It is estimated that 13.3 million people globally are affected by AKI every year, ~85% of which live in developing nations. The goals of CRRT for critically ill patients with AKI include maintaining fluid, electrolyte, acid-base, and solute balance, supporting renal recovery, and allowing other supportive interventions to proceed without complication or limitation.

Advantages Associated with CRRT Drives the Continuous Renal Replacement Therapy (CRRT) Market Growth
Critically ill patients with AKI undergoing Renal Replacement Therapy (RRT) often experience frequent episodes of hemodynamic instability. CRRT may have a better hemodynamic profile compared with other intermittent therapies, including intermittent hemodialysis (IHD) and sustained low-efficiency dialysis. Among the CRRT’s advantages, compared to other RRT, is preventing changes in intracerebral water. CRRT is also considered safer than IHD in patients at risk of cerebral edema.

Increasing Awareness Regarding Kidney Health & Prevention Program Drives the Continuous Renal Replacement Therapy (CRRT) Market
Presently, a large number of kidney health & prevention programs are run by organizations such as National Kidney Foundation (NKF), The National Kidney Disease Education Program (NKDEP), and local governments worldwide to raise awareness regarding evidence-based interventions to improve understanding, detection, and management of kidney disease.

For instance,

 In September 2022, Fresenius Medical Care, announced they have signed a memorandum of understanding (MoU) with the National Kidney Foundation
(NKF) Malaysia, this collaboration is to join efforts in raising awareness about kidney health and the prevention of chronic kidney disease amongst children and their families in Malaysia

Covid-19 Impact on the Continuous Renal Replacement Therapy (CRRT) Market
The global healthcare systems have faced significant challenges due to the COVID-19 pandemic. Among the patients hospitalized with COVID-19, a considerable proportion, ranging from 15% to 30%, exhibited signs of kidney failure and required Continuous Renal Replacement Therapy (CRRT). In these instances, CRRT acted as a life-sustaining and life-saving therapy.

Key Constraints of the Continuous Renal Replacement Therapy (CRRT) Market
The high cost of the CRRT procedures and the risk & complications associated with the CRRT such as catheter-related complications, blood loss, infection or access failure, fluctuations in salt balance, hemodialysis-related complications, coagulopathy, and venous thrombosis are likely to hinder the growth of the continuous renal replacement therapy market in the coming years.

North America Expected to Continue to Hold a large Share in the Continuous Renal Replacement Therapy (CRRT) Market
From a geographical outlook, North America holds a major market share of the continuous renal replacement therapy market. This can be primarily attributed to the growing incidences of AKI, technological advancements in continuous renal replacement therapy products, and an increase in the number of diabetic patients in North America.

Competitive Landscape Analysis of the Continuous Renal Replacement Therapy (CRRT) Market
Some of the key companies operating in the market include Baxter, B. Braun, Fresenius Medical Care AG, Medtronic, and Nipro Corporation, among others.

Organic and Inorganic Growth Strategies Adopted by Players to Establish Their Foothold in the Market
Companies operating in this market are adopting organic and inorganic growth strategies such as collaborations, acquisitions, and new product launches to garner market share.

Such as,

 In August 2022, Fresenius Medical Care closed a three-way merger including Fresenius Health Partners, the value-based care division of Fresenius Medical Care North America, and created a premier value-based kidney care provider in the U.S

 In April 2022, Baxter International Inc. announced the U.S. FDA 510(k) clearance of the company’s ST Set used in continuous renal replacement therapy (CRRT)

Our Research Report Addresses the Following Strategic Questions:

• What is the size and forecast of the market for continuous renal replacement therapy?

• What are the historical, current, and projected market shares and growth rates of the continuous renal
replacement treatment market's major segments and sub-segments?

• How has Covid-19 affected the market for continuous renal replacement therapy?

• What are the significant market growth drivers, constraints, and challenges?

• What are the current opportunities in the market for continuous renal replacement therapy?

• What is the investment landscape of the market for continuous renal replacement therapy?

• Which region accounts for the largest proportion of the worldwide CRRT market? Which region is
predicted to expand the fastest over the next five years?

Get Detailed Insights on the Continuous Renal Replacement Therapy (CRRT) Market @ https://meditechinsights.com/continuous-renal-replacement-therapy-market/